Literature DB >> 3716455

The metabolism of nicardipine hydrochloride in healthy male volunteers.

W R Rush, O Alexander, D J Hall, L Cairncross, R J Dow, D J Graham.   

Abstract

Four human volunteers given a 30 mg oral dose of nicardipine hydrochloride containing 40 microCi of the 14C-labelled material achieved peak plasma levels of compound-related radioactivity within one hour of dosing. Parent compound comprised only a minor fraction of the circulating radioactivity indicating rapid first-pass metabolism. Plasma radioactivity declined to background levels within 96 h and was excreted both in the urine and faeces. Urinary excretion was the favoured route comprising about 60% of the dosed radioactivity. Mean total recovered radioactivity amounted to 94.8%. Both 1,4-dihydropyridine and pyridine metabolites of nicardipine hydrochloride were excreted in the urine. The major urinary metabolites, comprising some 36% of the radioactivity excreted in the 0-8 h post-dose period, were the glucuronide conjugates of +/- 2-hydroxyethyl methyl-1,4-dihydro-2,6-dimethyl-4(m-nitrophenyl)-3,5-pyridine dicarboxylate and its pyridine from 2-hydroxyethyl methyl-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridine dicarboxylate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3716455     DOI: 10.3109/00498258609043537

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Urinary excretion of the 1,4-dihydropyridine calcium antagonist VULM 993 and its metabolites in the rat.

Authors:  M Stefek; V Faberova; S Musil; I Kakalik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 2.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics.

Authors:  P A Soons; T M Mulders; E Uchida; H C Schoemaker; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

6.  Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers.

Authors:  K J Hoffmann; L Andersson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism.

Authors:  P M Shaw; T S Barnes; D Cameron; J Engeset; W T Melvin; G Omar; J C Petrie; W R Rush; C P Snyder; P H Whiting
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

8.  Pharmacokinetic delivery and metabolizing rate of nicardipine incorporated in hydrophilic and hydrophobic cyclodextrins using two-compartment mathematical model.

Authors:  Sergey Shityakov; Carola Förster
Journal:  ScientificWorldJournal       Date:  2013-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.